PARP Inhibitor Maintenance Therapy after Initial Chemotherapy for Advanced Ovary, Fallopian Tube and Primary Peritoneal Cancers
Tune in for a 30-minute discussion of PARP maintenance after initial chemotherapy. This podcast discusses four trials examining the use of PARP inhibitors with initial chemotherapy that have recently been reported. These include:
- SOLO-1 that examines 2 years of olaparib maintenance in patients with BRCA mutations who responded to initial chemotherapy
- PAOLA-1 that examines the addition of olaparib maintenance to bevacizumab maintenance in patients who were treated with chemotherapy and bevacizumab
- PRIMA that examines niraparib maintenance after completion of initial chemotherapy for high risk patients
- VELIA that examines the use of veliprib with initial chemotherapy alone or with initial chemotherapy and as maintenance.
Podcast released in May 2020.
Keywords: BRCA, Clinical trial, Genetics, Chemotherapy, Maintenance therapy, PARPi, Pharmacology, Ovary, Molecular profile, Targeted, Homologous Recombination deficient
Physicians, Trainees, Residents, Fellows, APPs